PPT-Adherence and Acceptability for PrEP formulations

Jessica Haberer MD MS July 24 2017 Conflicts of Interest I have no conflicts to declare Grant funding US National Institutes of Health Bill and Melinda Gates Foundation USAID Consultation US National Institutes of Health World Health Organization Merck. Daniel Yang, MD Candidate*. Fogarty International Clinical Research Scholar. Research Institute for Health Sciences Institute (CMU). Johns Hopkins Bloomberg School of Public Health. International AIDS Conference. Bernard Vrijens, PhD. Chief Science Officer, MWV Healthcare. Associate Professor of Biostatistics . University of Liège, Belgium. Adherence is key to therapeutic success. 2. Effective. Disease. Management. Reasons why patients do not adhere. Measuring adherence and non adherence. Improving adherence. Reasons for non-adherence: cognitive rational non-adherence. Adherence is all about being conscientious in following medical advice. . Dispensary. Agenda. Introduction . Topical Formulations. Intranasal Formulations. Summary and Questions. Introduction. Historically, within Safety Assessment (GSK), standard formulations are generally used for:- . Angelica Lindsey-Ali & Calicia White. Ebony House Inc.. Objectives. By the end of this section, participants should be able to. : . Understand the difference between cultural humility and cultural competence. Oral . PrEP. in MSM. Division of Global HIV and TB, CDC, New Delhi, India. Timothy H. . Holtz . (CDC/DHAP / Thailand MOPH – US CDC Collaboration). and HPTN . 067/ADAPT Study . Team. MOSY08, IAS. , . Dr. Seema Sahay, Ph.D. Division of Social and Behavioral Research. National AIDS Research Institute. Indian Council of Medical Research, Pune (India). Overview. Defining and measuring adherence. Issues around adherence. Action. Improving Access to Optimized Treatment . for Children . Living with HIV. Melbourne, 22 July 2014. Marc Lallemant & Janice Lee. DNDi. mlallemant@dndi.org. Malaria. Leishmaniasis. With GLP-1 RAs. This program will include a discussion of investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form.. . These data should be considered preliminary until published in a . (Version 2.0). 2. Welcome!. Please sign the registration sheet.. Please make a name tag for yourself.. Please ta. ke a participant . manual, notebook, and pen. . Any component of this document may be reproduced or adapted without prior permission from ICAP, provided that: 1) ICAP is acknowledged; 2) appropriate attribution is given for all changes that are made; and 3) the material is made available free of charge. . HPTN 082: Evaluation of daily oral PrEP as a primary prevention strategy for young African women Connie Celum and Sinead Delany- Moretlwe HPTN 082/HERS co-chairs How do you create demand? What information is needed? AbstractBackground: The global burden is estimated to be 1% affecting over 65 million people it has profound physical, psychological and social impacts with a greater impact on a person’s quality EPF Position Paper March 2015 2 Adherence and Concordance EPF position paper , March 2015 Contents 1 Introduction ................................ ................................ .................... PrEP Counseling Center. What is Medication Adherence?. The World Health Organization defines medication adherence as the degree to which the person’s behavior corresponds with the agreed recommendations from a health care provider..